CJC-1295 + IPA (5/5ml)
$79.00
A research blend combining the GHRH analog CJC-1295 and the selective GHS agonist Ipamorelin, formulated for laboratory investigation of complementary somatotropic axis signaling pathways.
Buy 1
SAVE 0%
Buy 3
SAVE 20%
Buy 5
SAVE 33%
Buy 7+
SAVE 50%
Description
This research blend combines CJC-1295 (a modified GHRH analog with enhanced stability) and Ipamorelin (a selective GHSR agonist) in equal measure, pairing two peptides that act through complementary mechanisms on the hypothalamic-pituitary somatotropic axis. CJC-1295 mimics GHRH activity at pituitary somatotrophs, while Ipamorelin acts through the ghrelin receptor pathway — two pharmacologically distinct routes to GH secretion stimulation.
Laboratory research has explored the complementary nature of these signaling pathways, their combined effects on GH pulse amplitude and secretion profiles in preclinical models, and their comparative pharmacokinetics. This combination represents one of the most frequently studied pairings in growth hormone axis research, supported by a substantial body of preclinical and clinical literature for both individual compounds.
Supplied as a precision-blended Research Use Only (RUO) material, analytically verified for the identity and purity of both components, with batch-specific Certificate of Analysis documentation.
